Shandong Cost Of Revenue vs Ebitda Analysis

600529 Stock

24.41 0.19 0.77%

Shandong Pharmaceutical financial indicator trend analysis is much more than just breaking down Shandong Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Shandong Pharmaceutical is a good investment. Please check the relationship between Shandong Pharmaceutical Cost Of Revenue and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shandong Pharmaceutical Glass. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Shandong Pharmaceutical Cost Of Revenue account and Ebitda. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Shandong Pharmaceutical's Cost Of Revenue and Ebitda is 0.89. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Shandong Pharmaceutical Glass, assuming nothing else is changed. The correlation between historical values of Shandong Pharmaceutical's Cost Of Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Shandong Pharmaceutical Glass are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Cost Of Revenue i.e., Shandong Pharmaceutical's Cost Of Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Shandong Pharmaceutical income statement and represents the costs associated with goods and services Shandong Pharmaceutical provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Ebitda

Most indicators from Shandong Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Shandong Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shandong Pharmaceutical Glass. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of January 8, 2025, Selling General Administrative is expected to decline to about 177.4 M. In addition to that, Tax Provision is expected to decline to about 91.6 M

	2022	2023	2024	2025 (projected)
Operating Income	707.2M	898.9M	1.0B	1.1B
Total Revenue	4.2B	5.0B	5.7B	6.0B

Operating Income Total Revenue

Shandong Pharmaceutical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Net Receivables	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Other Assets	Other Liab	Short Term Investments	Net Tangible Assets	Other Stockholder Equity	Long Term Investments	Total Current Assets	Non Current Assets Total	Non Currrent Assets Other	Non Current Liabilities Total	Short Long Term Debt
Total Assets		0.27	0.98	1.0	0.99	0.97	0.94	-0.38	0.66	0.98	0.33	0.98	0.95	0.95	0.98	0.96	0.92	0.91	0.88	0.88	-0.67	0.9	0.88	0.32	0.85	0.37
Other Current Liab	0.27		0.31	0.25	0.32	0.29	0.38	-0.1	0.13	0.34	0.42	0.31	0.43	0.32	0.23	0.23	0.34	0.29	0.31	0.35	0.08	0.31	0.19	0.7	0.29	0.66
Total Current Liabilities	0.98	0.31		0.97	0.99	1.0	0.92	-0.44	0.67	0.98	0.41	1.0	0.95	0.98	0.99	0.94	0.96	0.84	0.86	0.91	-0.59	0.87	0.89	0.44	0.9	0.48
Total Stockholder Equity	1.0	0.25	0.97		0.98	0.96	0.94	-0.37	0.66	0.98	0.31	0.97	0.94	0.94	0.97	0.95	0.9	0.92	0.88	0.87	-0.68	0.9	0.88	0.29	0.83	0.34
Retained Earnings	0.99	0.32	0.99	0.98		0.99	0.94	-0.41	0.66	0.98	0.35	1.0	0.97	0.98	0.98	0.94	0.96	0.86	0.87	0.91	-0.6	0.88	0.89	0.41	0.89	0.47
Accounts Payable	0.97	0.29	1.0	0.96	0.99		0.91	-0.45	0.67	0.97	0.42	1.0	0.94	0.97	0.99	0.94	0.95	0.83	0.85	0.9	-0.58	0.86	0.88	0.45	0.89	0.48
Cash	0.94	0.38	0.92	0.94	0.94	0.91		-0.34	0.58	0.9	0.32	0.93	0.95	0.93	0.89	0.84	0.89	0.86	0.84	0.87	-0.58	0.87	0.8	0.29	0.82	0.46
Long Term Debt	-0.38	-0.1	-0.44	-0.37	-0.41	-0.45	-0.34		-0.82	-0.46	-0.43	-0.42	-0.31	-0.44	-0.46	-0.26	-0.44	-0.21	-0.28	-0.29	0.02	-0.29	-0.25	-0.14	-0.26	-0.23
Net Receivables	0.66	0.13	0.67	0.66	0.66	0.67	0.58	-0.82		0.7	0.2	0.66	0.59	0.64	0.68	0.59	0.65	0.56	0.71	0.65	-0.14	0.71	0.66	0.21	0.54	0.21
Inventory	0.98	0.34	0.98	0.98	0.98	0.97	0.9	-0.46	0.7		0.4	0.98	0.93	0.95	0.98	0.95	0.93	0.86	0.87	0.87	-0.6	0.87	0.88	0.42	0.85	0.39
Other Current Assets	0.33	0.42	0.41	0.31	0.35	0.42	0.32	-0.43	0.2	0.4		0.4	0.28	0.48	0.43	0.26	0.38	0.19	0.22	0.33	-0.11	0.2	0.22	0.51	0.38	0.51
Total Liab	0.98	0.31	1.0	0.97	1.0	1.0	0.93	-0.42	0.66	0.98	0.4		0.96	0.98	0.99	0.94	0.96	0.85	0.86	0.91	-0.59	0.87	0.89	0.45	0.9	0.49
Intangible Assets	0.95	0.43	0.95	0.94	0.97	0.94	0.95	-0.31	0.59	0.93	0.28	0.96		0.95	0.92	0.9	0.94	0.86	0.86	0.91	-0.56	0.88	0.86	0.42	0.88	0.53
Common Stock	0.95	0.32	0.98	0.94	0.98	0.97	0.93	-0.44	0.64	0.95	0.48	0.98	0.95		0.97	0.89	0.97	0.81	0.84	0.92	-0.57	0.84	0.86	0.41	0.92	0.52
Property Plant Equipment	0.98	0.23	0.99	0.97	0.98	0.99	0.89	-0.46	0.68	0.98	0.43	0.99	0.92	0.97		0.94	0.95	0.82	0.85	0.88	-0.62	0.85	0.89	0.39	0.89	0.39
Other Assets	0.96	0.23	0.94	0.95	0.94	0.94	0.84	-0.26	0.59	0.95	0.26	0.94	0.9	0.89	0.94		0.86	0.86	0.87	0.85	-0.63	0.87	0.9	0.43	0.83	0.29
Other Liab	0.92	0.34	0.96	0.9	0.96	0.95	0.89	-0.44	0.65	0.93	0.38	0.96	0.94	0.97	0.95	0.86		0.74	0.81	0.89	-0.52	0.8	0.84	0.44	0.91	0.54
Short Term Investments	0.91	0.29	0.84	0.92	0.86	0.83	0.86	-0.21	0.56	0.86	0.19	0.85	0.86	0.81	0.82	0.86	0.74		0.82	0.78	-0.65	0.87	0.77	0.19	0.67	0.36
Net Tangible Assets	0.88	0.31	0.86	0.88	0.87	0.85	0.84	-0.28	0.71	0.87	0.22	0.86	0.86	0.84	0.85	0.87	0.81	0.82		0.96	-0.33	0.99	0.97	0.43	0.88	0.37
Other Stockholder Equity	0.88	0.35	0.91	0.87	0.91	0.9	0.87	-0.29	0.65	0.87	0.33	0.91	0.91	0.92	0.88	0.85	0.89	0.78	0.96		-0.34	0.95	0.96	0.5	0.96	0.54
Long Term Investments	-0.67	0.08	-0.59	-0.68	-0.6	-0.58	-0.58	0.02	-0.14	-0.6	-0.11	-0.59	-0.56	-0.57	-0.62	-0.63	-0.52	-0.65	-0.33	-0.34		-0.37	-0.38	0.17	-0.36	0.03
Total Current Assets	0.9	0.31	0.87	0.9	0.88	0.86	0.87	-0.29	0.71	0.87	0.2	0.87	0.88	0.84	0.85	0.87	0.8	0.87	0.99	0.95	-0.37		0.95	0.38	0.86	0.37
Non Current Assets Total	0.88	0.19	0.89	0.88	0.89	0.88	0.8	-0.25	0.66	0.88	0.22	0.89	0.86	0.86	0.89	0.9	0.84	0.77	0.97	0.96	-0.38	0.95		0.43	0.93	0.32
Non Currrent Assets Other	0.32	0.7	0.44	0.29	0.41	0.45	0.29	-0.14	0.21	0.42	0.51	0.45	0.42	0.41	0.39	0.43	0.44	0.19	0.43	0.5	0.17	0.38	0.43		0.53	0.67
Non Current Liabilities Total	0.85	0.29	0.9	0.83	0.89	0.89	0.82	-0.26	0.54	0.85	0.38	0.9	0.88	0.92	0.89	0.83	0.91	0.67	0.88	0.96	-0.36	0.86	0.93	0.53		0.54
Short Long Term Debt	0.37	0.66	0.48	0.34	0.47	0.48	0.46	-0.23	0.21	0.39	0.51	0.49	0.53	0.52	0.39	0.29	0.54	0.36	0.37	0.54	0.03	0.37	0.32	0.67	0.54

Click cells to compare fundamentals

Shandong Pharmaceutical Account Relationship Matchups

Shandong Pharmaceutical fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.6B	6.4B	8.8B	9.3B	10.7B	11.3B
Other Current Liab	156.5M	117.6M	324.5M	69.9M	80.4M	131.4M
Total Current Liabilities	1.3B	1.7B	1.8B	1.7B	2.0B	2.1B
Total Stockholder Equity	4.3B	4.7B	7.0B	7.5B	8.7B	9.1B
Retained Earnings	2.7B	3.1B	3.5B	3.6B	4.1B	4.3B
Accounts Payable	995.8M	1.4B	1.4B	1.4B	1.6B	1.7B
Cash	1.1B	885.0M	1.4B	1.5B	1.7B	1.8B
Net Receivables	640.8M	764.4M	871.7M	970.1M	1.1B	622.7M
Inventory	749.2M	877.7M	1.2B	1.1B	1.2B	1.3B
Other Current Assets	82.5M	62.0M	104.6M	35.0M	40.3M	76.8M
Total Liab	1.4B	1.7B	1.8B	1.8B	2.1B	2.2B
Intangible Assets	203.3M	198.4M	260.4M	253.7M	291.7M	306.3M
Property Plant Equipment	1.9B	2.1B	2.6B	2.8B	3.2B	3.4B
Other Assets	64.4M	161.3M	319.4M	381.9M	439.2M	461.2M
Other Liab	49.7M	60.0M	60.0M	58.9M	67.8M	71.2M
Short Term Investments	230.5M	307.1M	1.1B	1.2B	1.4B	1.5B
Net Tangible Assets	3.7B	4.1B	4.5B	6.7B	7.7B	4.2B
Other Stockholder Equity	62.2M	64.4M	66.2M	75.5M	86.8M	59.8M
Total Current Assets	3.1B	3.3B	5.3B	5.5B	6.4B	3.7B
Non Current Assets Total	2.5B	3.1B	3.5B	3.8B	4.3B	2.7B
Non Currrent Assets Other	131.7M	287.0M	349.9M	16.8M	19.3M	18.3M
Non Current Liabilities Total	60.0M	60.0M	58.9M	57.6M	66.3M	51.7M
Net Invested Capital	4.3B	4.7B	7.0B	7.5B	8.7B	5.4B
Net Working Capital	1.8B	1.7B	3.6B	3.8B	4.4B	2.6B
Property Plant And Equipment Net	2.1B	2.6B	2.8B	3.5B	4.0B	2.8B
Property Plant And Equipment Gross	3.2B	3.8B	2.8B	5.2B	5.9B	3.9B

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in Shandong Stock

Balance Sheet is a snapshot of the financial position of Shandong Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Shandong Pharmaceutical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Shandong Pharmaceutical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Shandong currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shandong Cost Of Revenue vs Ebitda Analysis

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Ebitda

Shandong Pharmaceutical fundamental ratios Correlations

Shandong Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shandong Pharmaceutical fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shandong Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Retained Earnings
Total Liab	+ 1.0	Accounts Payable
Retained Earnings	+ 0.99	Total Assets

Net Receivables	- 0.82	Long Term Debt
Long Term Investments	- 0.68	Total Stockholder Equity
Long Term Investments	- 0.67	Total Assets
Long Term Investments	- 0.65	Short Term Investments
Long Term Investments	- 0.63	Other Assets
Long Term Investments	- 0.62	Property Plant Equipment